A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and the safety of a front-line treatment combining CHOP regimen and
rituximab in patients aged 60 to 80 years with previously untreated AIL.